Workflow
亿帆医药: 半年报董事会决议公告

Core Points - The company held its 18th meeting of the 8th Board of Directors, where all 8 directors participated and approved several key resolutions [1][2][3] Meeting Details - The meeting was convened in accordance with the Company Law and the Articles of Association, ensuring compliance with relevant regulations [1] - All resolutions were passed with unanimous support, with 8 votes in favor and no votes against or abstentions [2][3] Financial Reports - The Board approved the 2025 Half-Year Report and its summary, which will be disclosed on the company's official information platform [1] Board Elections - The Board approved the nomination of candidates for the 9th Board of Directors, including non-independent directors and independent directors, with all candidates receiving unanimous support [2][3] Amendments to Company Regulations - Several amendments to the company's internal regulations were approved, including revisions to the Articles of Association, Shareholders' Meeting Rules, and Board Meeting Rules [4][5][6] - The company also approved changes to the Independent Director Work System and the Management of Raised Funds [5][6] Independent Director Compensation - The Board approved an increase in the compensation for independent directors from RMB 100,000 to RMB 150,000 per year, reflecting the company's operational context and market conditions [6][7] Upcoming Shareholder Meeting - The Board resolved to convene the second extraordinary general meeting of shareholders in 2025 to discuss the approved resolutions [8]